- Low dose (200 mg) achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks.
- Higher 600 mg dose demonstrated deeper peripheral B-cell depletion with acceptable tolerability.
- Trial is ongoing with additional Phase 2 data expected in 2027.
?? Positive AI Sentiment (+6.5 / 10)
Observed market reaction after signal
4h -6.48% · Peak +0.10%